A0587 Non-luminal molecular subtypes demonstrate highest complete response rates after neoadjuvant chemo-immune therapy for muscle-invasive bladder cancer: Biomarker analyses of NURE-combo & BLASST-01 phase 2 clinical trials

European Urology 2026

View at publisher
Authors: J.J. De Jong, Chiara Mercinelli, Giuseppe Basile, J.A. Proudfoot, Antonio Cigliola, Valentina Tateo, B. Maiorano, E. Davicioni, M. Colecchia, Marco Moschini, Giorgio Brembilla, F. De Cobelli
+4 more Alberto Briganti, Francesco Montorsi, S. K. Gupta, A. Necchi
DOI: 10.1016/s0302-2838(26)00638-x
Cited by: 0

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Breast Cancer Treatment Studies Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
European Urology
Volume
89
Pages
S1–S1
Publication date
13 February 2026
Language
EN